The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
The embattled company saw its net loss narrow during the first quarter, in part due to a new policy of giving away fewer nonreimbursed GPS Cancer and Liquid GPA molecular test orders than in the past.
The liquid biopsy firm beat analyst estimates on the top and bottom lines and raised full-year revenue guidance to $145 to $150 million.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
The company posted Q1 revenues of $12.3 million, up from $7.5 million in Q1 2018 and above the consensus Wall Street estimate of $10.2 million.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.
The company saw $1.0 million in revenues for the quarter, including $976,000 from commercial testing, and attributed the growth to its pathology partnership initiative.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The revenue increase was driven by a jump in sales of products including the company's flagship Epi proColon blood-based colorectal cancer screening test.
For the three months ended March 31, the firm generated $40.6 million in revenues, missing the consensus Wall Street estimate of $47.2 million.
The firm reported total revenues of $216.6 million in Q3 2019 compared to $183.1 million a year ago, but it fell short of the consensus Wall Street estimate was $217.5 million.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
The test is designed to determine breast cancer risk by analyzing a number of factors including breast density, breast biopsy history, and a polygenic score.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.
According to PathGroup, the deal will broaden its testing menu and adds more than 120 pathologists covering all pathology sub-specialties to the company.